Immuneering Corporation
IMRX
$3.95
-$0.09-2.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.68M | 4.49M | 4.51M | 4.30M | 4.01M |
| Depreciation & Amortization | 7.30K | 7.30K | 7.30K | 7.30K | 7.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.34M | 13.75M | 15.38M | 14.76M | 15.48M |
| Operating Income | -15.34M | -13.75M | -15.38M | -14.76M | -15.48M |
| Income Before Tax | -13.46M | -11.58M | -14.96M | -14.43M | -15.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.46M | -11.58M | -14.96M | -14.43M | -15.05M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.46M | -11.58M | -14.96M | -14.43M | -15.05M |
| EBIT | -15.34M | -13.75M | -15.38M | -14.76M | -15.48M |
| EBITDA | -15.25M | -13.67M | -15.29M | -14.67M | -15.39M |
| EPS Basic | -0.21 | -0.18 | -0.38 | -0.40 | -0.42 |
| Normalized Basic EPS | -0.13 | -0.11 | -0.24 | -0.25 | -0.26 |
| EPS Diluted | -0.21 | -0.18 | -0.38 | -0.40 | -0.42 |
| Normalized Diluted EPS | -0.13 | -0.11 | -0.24 | -0.25 | -0.26 |
| Average Basic Shares Outstanding | 64.66M | 64.59M | 39.67M | 35.99M | 35.53M |
| Average Diluted Shares Outstanding | 64.66M | 64.59M | 39.67M | 35.99M | 35.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |